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ABSTRACT: The treatment of childhood cancer with chemotherapy drugs can result in infertility in adulthood. Newer generations of drugs
are developed to replace parent drugs, with the potential benefits of less toxic side effects. For platinum alkylating-like drugs, in contrast to
the parent compound cisplatin, the newer-generation drug carboplatin is reported to have reduced toxicity in some respects, despite being
administered at 5–15 times higher than the cisplatin dose. Whether carboplatin is also less toxic than cisplatin to the reproductive system
is unknown. Here we compare the gonadotoxic impact of cisplatin and carboplatin on female and male mouse prepubertal gonads. In vitro
cultured CD1 mouse ovaries or testis fragments were exposed to either cisplatin or carboplatin for 24 h on Day 2 of culture and analysed by
Day 6. A dose response for each drug was determined for the ovary (0.5, 1 & 5 μg/ml cisplatin and 1, 5 & 10 μg/ml carboplatin) and the testis
(0.01, 0.05 & 0.1 μg/ml cisplatin and 0.1, 0.5 & 1 μg/ml carboplatin). For the ovary, unhealthy follicles were evident from 1 μg/ml cisplatin (73%
unhealthy, P =0.001) and 5 μg/ml carboplatin (84% unhealthy, P =0.001), with a concomitant reduction in follicle number (P =0.001). For
the testis, the proliferating germ cell population was significantly reduced from 0.05 μg/ml cisplatin (73% reduction, P =0.001) and 0.5 μg/ml
carboplatin (75% reduction, P =0.001), with no significant impact on the Sertoli cell population. Overall, results from this in vitro animal model
study indicate that, at patient equivalent concentrations, carboplatin is no less gonadotoxic than cisplatin.
Key words: chemotherapy / fertility preservation / ovary / follicles / testis / spermatogonia / tissue culture / gonadotoxicity
Introduction
Childhood cancer survival rates have markedly increased in recent
decades, with the current 5-year survival rate across all childhood
cancers above 80% (Miller et al., 2016). This improvement can be
attributed in large part to the increasing use of chemotherapy drugs
in treatment regimens since their introduction to clinical practice in the
early 1940s (Devita and Chu, 2008), along with targeted therapies such
as radiotherapy, immunotherapy and surgery. Multiple chemotherapy
agents have been developed targeting malignant tumours through
various mechanisms, with treatment most often combining different
classes of drugs (Lind, 2011). However, damage to healthy tissues can
arise as a side effect of chemotherapy treatment, since these cytotoxic
drugs can target normal cells as well as malignant ones. It is becoming
increasingly apparent that a vast majority of childhood cancer survivors
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are living with long-term chronic health conditions as a result of the
treatment they received (Oeffinger et al., 2006; Hudson et al., 2013;
Robison and Hudson, 2014; Bhakta et al., 2017). The impact upon
future fertility has been extensively studied, and there are now clear
links between the use of alkylating chemotherapy agents in treatment
regimens for childhood cancers and subsequent impairment of fertility
(Anderson and Wallace, 2016; Stukenborg et al., 2018; Newton et al.,
2019). Indeed, a study by Chow et al. (2016) has shown a reduced
fertility rate for male and, to a lesser extent, female survivors of
childhood cancer in comparison to their siblings. In short, it is clear
that certain chemotherapy agents damage the reproductive systems of
those children undergoing treatment. The most commonly used drugs
have been broadly classified according to their predicted risk to future
fertility, although these classifications are a matter of debate (Wallace
et al., 2005; Wyns et al., 2010; Wallace, 2011). Many studies are based
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on historic treatment protocols that may be outdated and also more
aggressive in comparison to current oncology regimens, with newer
generations and combinations of drugs considered to bemore effective
with reduced side effects. As a result, more information is needed on
these newer protocols and generations of drugs in order to determine
the risk of subsequent infertility for today’s patients.
Platinum alkylating-like chemotherapy drugs are commonly used in
paediatric oncology treatment regimens for multiple different types of
cancer, including germ cell tumours, carcinomas, lymphomas and sarco-
mas (Dasari and Tchounwou, 2014). Development of these platinum-
containing compounds has resulted in different generations including
cisplatin (1st generation) and carboplatin (2nd generation) (Weiss
and Christian, 1993). These drugs are composed of doubly charged
platinum ions surrounded by four ligands: two amine groups and two
‘leaving groups’ (Desoize and Madoulet, 2002) (Fig. 1). Once inside the
cell, the drugs are hydrolysed to form active metabolites that bind to
and damage cellular DNA, RNA and proteins, resulting in activation
of cell death pathways. Toxicity is mainly attributed to DNA damage
where the active metabolites bind to purine bases resulting in cross-
linking of the DNA (Dasari and Tchounwou, 2014). However, other
molecular mechanisms have been linked to the clinical activity of these
drugs, including induction of oxidative stress, modulation of calcium
signalling and activation of cellular pathways (Dasari and Tchounwou,
2014). Cisplatin is associated with many toxic side effects including
emesis, nephrotoxicity, neurotoxicity, myelosuppression, immunosup-
pression and ototoxicity; together, these side effects can limit the
use of cisplatin in treatment protocols (Florea and Büsselberg, 2011).
Cisplatin has been broadly classified as gonadotoxic for paediatric
patients (Wyns et al., 2010; Chow et al., 2016), a categorisation that
has been backed up by animal model studies (reviewed in Morgan
et al., 2012; Allen et al., 2018). Newer generations of this class of
drugs have been developed with reduced toxicity; so far, carboplatin
is the main drug which has been widely and successfully used as a
replacement of cisplatin, although only for certain cancers (Weiss and
Christian, 1993; Go and Adjei, 1999). Pharmacologically, carboplatin is
8–45 times less potent than cisplatin for certain cancers and is more
stable, possibly due to reduced aquation rates and DNA-damaging
effects (Micetich et al., 1985; Knox et al., 1986; reviewed in: Ruggiero
et al., 2013; Dasari and Tchounwou, 2014) (Fig. 1). As a consequence,
clinically, carboplatin is administered at higher doses in order to be
as effective as cisplatin (Hongo et al., 1994; Dasari and Tchounwou,
2014). From published paediatric patient doses, the administered dose
of carboplatin can range from 5–15 times higher than the administered
dose of cisplatin (Crom et al., 1981; Dominici et al., 1989; Madden
et al., 1992; Murry et al., 1993; Newell et al., 1993; Riccardi et al., 1994;
Peng et al., 1997; Erdlenbruch et al., 2001; Clerico et al., 2006; Veal
et al., 2007). So far, few studies have focused upon the toxicity of
newer generations of platinum alkylating-like agents, although carbo-
platin has been reported to reduce damage to the kidneys in com-
parison to cisplatin (Canetta et al., 1985). However, myelosuppression
and emesis remain associated side effects of both drugs (Canetta
et al., 1985). As with cisplatin, carboplatin is currently considered as
gonadotoxic based on current classification systems (Wallace et al.,
2005; Wyns et al., 2010; Lambertini et al., 2016), although to the best
of the authors’ knowledge, no studies have focused specifically on the
gonadotoxicity of carboplatin in paediatric patients or in prepubertal
animal models.
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Figure 1 Molecular structure of platinum-alkylating
chemotherapy agents and active metabolites formed
following aquation of parent drug. Cisplatin and carboplatin
share a similar chemical structure with a core platinum ion surrounded
by two ‘amine groups’ and two ‘leaving groups’. Cisplatin and
carboplatin differ in the leaving groups as shown: cisplatin is
composed of chloride ion leaving groups whereas carboplatin
contains cyclobutane-decarboxylate leaving groups. Once inside
cells, the leaving groups are displaced by water forming aquated
active metabolites. The chloride leaving groups of cisplatin readily
dissociate whereas the cyclobutane-decarboxylate groups have
reduced aquation rates requiring an esterase to dissociate from the
parent compound. As a result, cisplatin and carboplatin have different
rates of aquation which could account for the reduced clinical activity
of carboplatin requiring higher doses to be administered to patients
for the drug to be as effective as cisplatin (Ho et al., 2016).
This study used cultured prepubertal ovaries and testes to compare
the gonadotoxicity of carboplatin and cisplatin. In vitro systems are
widely used to test and compare different drugs in reproductive
toxicology (Stefansdottir et al., 2014), and the methods used here
are well-established models for culturing immature mouse gonadal
tissue, supporting the health and physiological development of control
cultured tissue (see for example Morgan et al., 2013; Smart et al.,
2018). Whereas whole ovaries can remain healthy when cultured
intact, the size of the testes results in large areas of necrosis if cultured
whole, and so testicular tissue was dissected into small fragments
prior to culture as carried out previously by ourselves and others
(see for example Sato et al., 2011; Lopes et al., 2016; Smart et al.,
2018). To compare the two drugs in both the ovary and the testis, a
dose response for each drug was first obtained in order to determine
a lowest dose that had no effect on that tissue and a highest dose
that induced maximal damage, resulting in few, if any, healthy follicles
in the ovary or surviving germ cells in the testis. The resulting dose
response concentrations fall within clinical patient serum levels for each
drug, with tissues exposed to higher concentrations of carboplatin than
cisplatin, reflecting the relative dose administered to patients (Ruggiero
et al., 2013).
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Methods
Animals
Experiments were approved by theUniversity of Edinburgh’s Local Eth-
ical Review Committee and carried out in accordance with UK Home
Office regulations. CD1 mice were housed in an approved animal facil-
ity and kept in a 14-hr light:10-hr dark cycle, with food and drink pro-
vided ad libitum. Animals were sacrificed through cervical dislocation.
Chemotherapy drugs
Cisplatin and carboplatin (Millipore, UK) were purchased in powder
form, made up in distilled water to stock solutions of 1 mg/ml cisplatin
and 10 mg/ml carboplatin. The chemotherapy drugs were added to
the culture medium to produce final concentrations that resulted in a
dose response for each tissue that ranged from a lowest dose that had
no significant effect to a highest dose that affected the health (ovary) or
number (testis) of the vast majority of germ cells. The dose response
was based upon the health/number of the follicles/germ cells at the
end of the culture period. For the ovary, concentrations of 0.5, 1 and
5 μg/ml cisplatin and 1, 5 and 10 μg/ml carboplatin were added; for
the testis, lower concentrations of 0.01, 0.05 and 0.1 μg/ml cisplatin
and 0.1, 0.5 and 1 μg/ml carboplatin were sufficient to produce the
required dose response: all doses used were broadly within the range
that has been found in patient serum, as detailed below.
Culture systems
Prepubertal mouse ovary and testis culture systems were performed
as previously described and validated (Lopes et al., 2016; Smart et al.,
2018), using hormone- and antibiotic-free culture conditions. Briefly,
ovaries (postnatal day 4; pnd4) and testes (pnd5) were dissected
and placed in Leibovitz L-15 medium (Invitrogen, UK) supplemented
with 3 mg/ml bovine serum albumin (BSA; Sigma, UK) prewarmed
to 37◦C.
Ovary culture
For each experimental run, ovaries were dissected from all females
within a litter, with the ovaries then randomly distributed across
treatment groups. Non-gonadal tissues were removed, and each ovary
was cultured upon a floating polycarbonate membrane (Whatman
Nuclepore Polycarbonate Membrane, Camlab Ltd, Cambridge, UK) in
a 24-well plate (Greiner Bio-One, Stonehouse, UK) containing 1 ml α-
minimum essential media (α-MEM, Invitrogen, UK) supplemented with
3 mg/ml fatty acid free BSA (Sigma, UK) and incubated at 37◦C with
5% CO2 (Day 1). Following 24 h of chemotherapy exposure (Day 2),
tissues were removed and placed in a drug-freemedium until the end of
culture (Days 3–6), with media changes every 2/3 days. Vehicle control
cultures containing drug-free media supplemented with water in place
of drugs were maintained throughout the culture period. Tissues were
fixed in Bouin’s (Sigma, UK) for morphological analysis. For all groups,
six ovaries were analysed (n =6), obtained from at least four separate
litters.
Testis culture
For each culture experiment, testes were obtained from two or three
pups from the same litter. Non-gonadal tissues and surrounding tunica
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were removed, and testes were dissected into roughly 0.1-mm3 frag-
ments using a blade (Altomed, UK), with the testicular fragments then
randomly distributed across treatment groups. Each fragment was
cultured on a floating membrane within a 24-well plate containing 1 ml
α-MEM media supplemented with 10% knockout serum replacement
(Invitrogen, UK). Tissues were cultured at 37◦C in 5% CO2. After
a settling in period of 24 h (Day 1), tissues were exposed to drugs
for 24 h (Day 2), after which the floating membranes were moved
into drug-free media (Day 3). To determine the proliferative capacity
of tissues, 15 μg/ml of bromodeoxyuridine (BrdU; Sigma, UK) was
added for the final 24 h of culture (Day 4). Vehicle control cultures
containing drug-free media supplemented with water were maintained
throughout the culture period. At end of the culture period, tissues
were fixed in 10% neutral buffered formalin (NBF; Sigma, UK) for
immunohistochemistry. For all groups, six fragments were analysed
(n =6), obtained from at least three separate litters.
Morphological evaluation of ovary
Fixed ovaries were embedded in paraffin and 5-μm sections cut. To
evaluate morphology, follicle number, class and health were deter-
mined as in Morgan et al. (2013). Every sixth section was analysed,
with total follicle counts estimated using the Abercrombie formula
(Abercrombie, 1946). Tissues were stained with haematoxylin and
eosin (H&E); images were taken with a DMLB Leica microscope (Leica
Microsystems Ltd, UK) and analysed using ImageJ software ( JAVA) with
the assessor blind to experimental conditions. Follicles were included
in the count only where germinal vesicles were visible. Follicle stage
and health were determined based on appearance of granulosa cells
and oocytes as described in Morgan et al. (2013). Follicles were classed
as either primordial, transitional or primary, with overall health deter-
mined using standard morphological criteria as either unhealthy due to
damage to the oocytes (Fig. 2 Aii, white arrowhead), to the granulosa
cells (Fig. 2 Aiii, black arrowhead) or to both cell types. Oocyte damage
was characterised based on the appearance of shrunken, eosinophilic
cytoplasm or condensed nuclear chromatin, while granulosa cell dam-
age was evidenced by the condensed chromatin or irregular overall
shape of at least one granulosa cell, as detailed in previous work by
ourselves and others (see for example Springer et al., 1996; Muruvi
et al., 2005; Morgan et al., 2013; Lopes et al., 2014, 2016).
Immunohistochemistry of testis
Fixed testis fragments were embedded in paraffin and serially sectioned
at 5 μm. Every fifth section was immunostained. In brief, slides were
dewaxed, rehydrated and subjected to antigen retrieval with citrate
buffer (10 mM sodium citrate, pH 6, Fisher Chemical, UK). Slides
were blocked in 20% goat serum in PBS (Thermo Fisher Ltd, UK)
with 0.1% Triton X-100 (PBST; Sigma, UK) and 5% BSA for 1 h.
Primary antibodies were incubated overnight at 4◦C and secondary
antibodies for 1 h at room temperature in 10% goat serum, PBST and
5% BSA; see Table I for all antibody details. Slides were counterstained
with DAPI (Invitrogen, UK) and mounted with Vectashield mount-
ing medium (Vector Laboratories, USA). Images were taken (Leica
DM4400B microscope on a DFC360FX camera) and analysed using
ImageJ ( JAVA) with the assessor blind to experimental conditions. The
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Figure 2 Follicle number and health are reduced following cisplatin or carboplatin treatment. (A) Representative histological sections
of (Ai) control, (Aii) cisplatin (1 μg/ml) and (Aiii) carboplatin (5 μg/ml) exposed tissue; insets show higher magnification of framed areas. White
arrowhead shows example of a damaged oocyte; black arrowhead shows example of a damaged granulosa cell; scale bars represent 50 μm, or 20 μm
for insets. (B) Histograms show (Bi) total follicle number and (Bii) the percentage of unhealthy follicles following exposure to cisplatin (red) or carboplatin
(blue); n =6 for all experimental conditions. Data are mean+ SEM; columns without letters in common are statistically significantly different to each
other (P < 0.05).
density of total proliferating germ cells (MVH-positive/BrdU-positive),
non-proliferating germ cells (MVH-positive/BrdU-negative) and prolif-
erating Sertoli cells (SOX9-positive/BrdU-positive) were determined
through manual counting per area of seminiferous tubule. Area of
fluorophore expression for Sertoli cells (SOX9-positive) per area of
seminiferous tubules was used to determine density of Sertoli cells as
described in Smart et al. (2018).
Statistical analysis
Statistical analysis was performed using Minitab statistical software pro-
gramme version 17 (Minitab Inc., State College, PA, USA), and graphs
were created using GraphPad Prism software version 5 (GraphPad
Software, Inc., CA, USA). A one-way ANOVA with general linear
mixed effect model was used to determine statistical significance of
treatment, with effect of culture run taken into account; results were
deemed statistically significant at P < 0.05. Tukey pairwise comparison
test determined statistical significance between the experimental con-
ditions. Histograms of results are represented as mean+ SEM. Signifi-
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cance between groups is symbolised on graphs by letters, with different
letters indicating a statistical significance difference with individual P
values of P < 0.05.
Results
Cisplatin or carboplatin exposure reduces
the number and health of follicles in the
prepubertal ovary
In order to assess the effects of cisplatin or carboplatin treatment,
ovaries were examined after exposure in vitro to a range of concen-
trations that gave a dose response (cisplatin—0.5, 1 and 5 μg/ml;
carboplatin—1, 5 and 10 μg/ml; Fig. 2A). Total follicle number was
reduced compared to controls following exposure to all concentrations
of cisplatin, with a reduction from 0.5 μg/ml (40%; P =0.007), 1 μg/ml
(66%; P=0.001) and 5 μg/ml (61%; P=0.001) and from 5 μg/ml (60%;
P=0.001) and 10 μg/ml (62%; P=0.001) of carboplatin (Fig. 2 Bi). The
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Table I Primary and secondary antibodies for double immunohistochemistry.
Antigen 1 Dilution Secondary Antibody
for Antigen 1
Antigen 2 Dilution Secondary Antibody
for Antigen 2
.........................................................................................................................................................................................
Mvh (ab27591) 1:200 GAMou-488 BrdU (ab6326) 1:500 GARat-568
Sox9 (ab5535) 1:500 GARab-488 BrdU (ab6326) 1:500 GARat-568
Primary antibodies (antigen 1 and 2) purchased from Abcam, UK, and Secondary antibodies purchased from Invitrogen, UK.
Figure 3 Cisplatin or carboplatin treatment reduces the number of primordial follicles while damaging the health of all follicles.
(A) number and (B) percentage of follicles classified as unhealthy for (i) primordial, (ii) transitional or (iii) primary follicles following cisplatin (red) or
carboplatin (blue) treatment, n=6 for all experimental conditions. Data aremean+ SEM; columns without letters in common are statistically significantly
different to each other (P < 0.05).
percentage of unhealthy follicles increased in a dose-dependent man-
ner when exposed to at least 1 μg/ml of cisplatin (73+ 11% unhealthy;
P =0.001) and 5 μg/ml carboplatin (84+ 9% unhealthy; P =0.001) in
comparison to the control (Fig. 2 Bii). At the highest concentrations,
almost all follicles were unhealthy at 5 μg/ml cisplatin (100% unhealthy;
P =0.001) and 10 μg/ml carboplatin (97+ 1% unhealthy; P =0.001).
Cisplatin or carboplatin targets follicles
independent of stage
Since the number and health of the follicles were reduced following
treatment with either drug, the follicles were further classified as
primordial, transitional or primary to determine if a particular follicle
class was targeted. Both cisplatin and carboplatin reduced the number
of primordial follicles in comparison to the control from 0.5 μg/ml
cisplatin (44%; P =0.004) and 5 μg/ml carboplatin (65%; P =0.001)
(Fig. 3 Ai). There was little effect of cisplatin or carboplatin treatment
on the number of growing transitional or primary follicles, although
a trend towards a decrease in transitional follicles was noted, with
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a significant reduction in number at 1 μg/ml (56%; P =0.029) of
cisplatin only (Fig. 3 Aii,iii). When follicle health rather than number
was examined, the percentage of unhealthy follicles increased for all
classes in a dose-dependent manner. Damage to the primordial follicles
was evident from 1 μg/ml cisplatin (74+ 12% unhealthy; P =0.001)
and 5 μg/ml carboplatin (87+ 9% unhealthy; P =0.001) (Fig. 3 Bi). A
significant number of unhealthy transitional follicles was observed from
1 μg/ml cisplatin (75+ 13% unhealthy; P =0.001) and 5 μg/ml car-
boplatin (83+ 12% unhealthy; P =0.001) (Fig. 3 Bii). For the primary
follicles, damage was seen from 0.5 μg/ml cisplatin (53+ 7% unhealthy;
P =0.005) and 5 μg/ml carboplatin (56+ 8% unhealthy; P =0.002)
(Fig. 3 Biii).
Granulosa cells of primary follicles are
damaged by cisplatin or carboplatin
exposure
The health of each primary follicle was assessed depending upon
whether the oocyte and/or granulosa cells were damaged following
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Figure 4 Granulosa cells of the primary follicles are damaged by cisplatin or carboplatin. Percentage of primary follicles classed as
unhealthy due to (Ai) oocyte, (Aii) granulosa cell or (Aiii) combined (oocyte and granulosa cell) damage following cisplatin (red) or carboplatin (blue)
treatment, n =6 for all experimental conditions. Data are mean+ SEM; columns without letters in common are statistically significantly different to
each other (P < 0.05). Representative images show (Bi) healthy primary follicle (Bii) primary follicle with damaged oocyte, (Biii) primary follicle with
damaged granulosa cells and (Biv) primary follicles with combined (oocyte and granulosa cell) damage. Scale bar = 10 μm.
cisplatin or carboplatin exposure (Fig. 4). This analysis was not carried
out for primordial or transitional follicles due to the difficulty of prop-
erly assessing the health of flattened granulosa cells. In primary follicles,
either cisplatin or carboplatin treatment damaged the granulosa cells
in comparison to control. These effects were seen from 0.5 μg/ml
cisplatin (46+ 7% unhealthy; P =0.037) and from 5 μg/ml carboplatin
(45+ 10% unhealthy; P =0.049) (Fig. 4 Aii).
Cisplatin or carboplatin exposure reduces
the proliferating germ cell population in the
prepubertal testis
To determine the impact of cisplatin or carboplatin treatment on the
prepubertal testis, testicular fragments were exposed to cisplatin (0.01,
0.05 and 0.1 μg/ml) or carboplatin (0.1, 0.5 and 1 μg/ml) in vitro (Fig. 5
A). Germ cells (MVH-positive) were counted and classified as pro-
liferating (MVH-positive/BrdU-positive) or non-proliferating (MVH-
positive/BrdU-negative). The density of the total germ cell population
was significantly reduced in a dose-dependent manner evident from
0.05 μg/ml cisplatin (71% decrease; P =0.001) and 0.5 μg/ml carbo-
platin (75% decrease; P =0.001) (Fig. 5 Bi). A low density of germ cells
remained after treatment at the highest concentrations of both drugs in
comparison to control with 15% of germ cells remaining after cisplatin
(0.1 μg/ml; P =0.001) and 12% after carboplatin (1 μg/ml; P =0.001)
treatment. Cisplatin and carboplatin both affected the proliferating
germ cell population (MVH-positive/BrdU-positive), with the density
significantly decreased in a dose-dependentmanner following exposure
to at least 0.05 μg/ml cisplatin (73% decrease; P=0.001) and 0.5 μg/ml
carboplatin (75% decrease; P =0.001) (Fig. 5 Bii). A small population
of non-proliferating germ cells (MVH-positive/BrdU-negative) was
observed in the control tissue, with a similar density (∼400+ 30 cells
per mm2 of tubule) of these cells maintained across all experimental
groups.
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Sertoli cell density is unaffected by either
cisplatin or carboplatin exposure
To assess whether the damaging effect of cisplatin or carboplatin
exposure on germ cell density was also seen on the somatic cells
present within the seminiferous tubules, we determined the overall
density of Sertoli cells (SOX9-positive) (Fig. 6 A). This was unaffected
by cisplatin or carboplatin exposure (P =0.641) (Fig. 6 Bi). Similarly,
the proliferative capacity of these cells (SOX9-positive/BrdU-positive)
were also not altered by exposure to either drug (P=0.283) (Fig. 6 Bii).
Discussion
Prepubertal mouse ovaries and testes were exposed to a range of
concentrations of either cisplatin or carboplatin in culture, within
patient relevant concentrations; both drugs induced a dose-dependent
response. In order to achieve a similar clinical efficacy, carboplatin must
be administered at concentrations 5–15 times higher than cisplatin
(Hongo et al., 1994; Dasari and Tchounwou, 2014). Here, results show
that for ovarian tissue, two to five times carboplatin concentrations
(1, 5 and 10 μg/ml) in comparison to cisplatin (0.5, 1 and 5 μg/ml)
induced equivalent levels of damage to the follicles, which resulted in
significant effects at or above 1 μg/ml cisplatin and 5 μg/ml carboplatin
in terms of health. For the testicular tissue, 10 times carboplatin doses
(0.1, 0.5 and 1 μg/ml) were required to induce a similar reduction
in germ cell density compared to cisplatin doses (0.01, 0.05 and
0.1 μg/ml), resulting in significant effects at or above 0.05 μg/ml
cisplatin and 0.5 μg/ml carboplatin.
This is the first study to compare the effects of cisplatin or car-
boplatin exposure on the prepubertal gonad in females and males.
Several clinical studies in adults have compared the efficacy, survival and
toxicities of these drugs in treating a range of cancers where cisplatin
has, in general, better survival rates and efficacy while carboplatin has a
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Figure 5 Cisplatin or carboplatin treatment results in a significant loss of the proliferating germ cells. (A) Representative images of
histological sections from (Ai) control, (Aii) cisplatin (0.05 μg/ml) and (Aiii) carboplatin (0.5 μg/ml) treated testis, showing a reduction in the density of
proliferating germ cells (MVH-positive, green; BrdU-positive, red). Insets show higher magnification of framed areas. White arrowhead shows example
of a proliferating germ cell (MVH-positive/BrdU-positive); yellow arrowhead shows example of a non-proliferating germ cell (MVH-positive/BrdU-
negative). Scale bars represent 50 μm, or 25 μm for insets. (B) Density of germ cells per seminiferous tubule area (mm2) following cisplatin (red)
or carboplatin (blue) treatment. Data shows the density of the (Bi) total, (Bii: open bars) proliferating and (Bii: hatched bar) non-proliferating germ
cells; n =6 for all experimental conditions. Data are mean+ SEM; columns without letters in common are statistically significantly different to each
other (P < 0.05). For (Bii), letters refer to proliferating germ cells (open bars) only, with no statistically significant difference between groups for the
non-proliferating germ cells (hatched bars).
better toxicity profile; however, this is not the case for all malignancies
(reviewed in Ho et al., 2016). For paediatric patients, carboplatin has
been found to be as effective as cisplatin in treating germ cell tumours
with the added benefit of a reduced toxicity profile (Ruggiero et al.,
2013; Frazier et al., 2018; Shah et al., 2018). The toxicity of these
platinum alkylating-like drugs is mainly attributed to the formation of
DNA adducts, resulting in cross-linkage and subsequent DNA damage:
whether there is any underlying mechanism that may account for the
observed differences in toxicity prolife of these two drugs is, however,
not yet clear (reviewed in Siddik, 2003; Dasari and Tchounwou, 2014).
One study in cancer cell lines has identified a potential difference
between the two drugs, with cisplatin producing higher levels of
oxidative stress than carboplatin at patient-equivalent concentrations
(Marullo et al., 2013); it might be of interest to explore the oxidative
stress response to cisplatin and carboplatin in the gonads in future
studies. Our study compares the effects of these drugs on prepubertal
gonadal tissues and found, relative to the concentrations of each drug
in patient serum, gonadotoxicity resulting from carboplatin exposure
was at least as bad as that resulting from cisplatin exposure (patient
serum levels: cisplatin—0.05-4 μg/ml; Crom et al. 1981; Dominici et al.
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1989; Peng et al. 1997; Erdlenbruch et al. 2001 and carboplatin—0.5–
90 μg/ml; Madden et al., 1992; Murry et al., 1993; Newell et al., 1993;
Riccardi et al., 1994; Clerico et al., 2006; Veal et al., 2007). This is of
particular importance, as carboplatin as a second-generation drug of
the platinum alkylating-like class was developed as an alternative to
cisplatin in part due to reduced nephrotoxicity, ototoxicity and emesis
for paediatric patients (reviewed in Ruggiero et al., 2013). Overall,
carboplatin doses of two to five times for the ovary and 10 times
for the testis were found to be as damaging as equivalent cisplatin
concentrations. The same conclusion was also reached in an in vivo
study of adult mice based on the morphology of the testis, where
10 times carboplatin was found to be as gonadotoxic as cisplatin
(Köpf-Maier, 1992). Reduced spermatogenesis and altered structure of
the seminiferous tubules were observed, as well as decreased integrity
of Sertoli cells disrupting tight junction contact, a factor that was not
investigated in our study. Another such study of adult males found
carboplatin to be less toxic than cisplatin with regard to steroidogenesis
(Azouri et al., 1989): our study did not investigate the impact on
steroidogenesis. Our data from this in vitro, animal model study suggests
that replacing cisplatin with carboplatin in treatment regimens will not
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Figure 6 Density and proliferation of Sertoli cells are not affected by cisplatin or carboplatin. (A) Representative images of (Ai)
control, (Aii) cisplatin (0.05 μg/ml) and (Aiii) carboplatin (0.5 μg/ml) treated tissues showing no change in density of Sertoli cells (SOX9-positive;
green) or in proliferating Sertoli cells (SOX9-positive/BrdU-positive; orange). Insets show higher magnification of framed areas. White arrowhead
shows example of a proliferating Sertoli cell; yellow arrowhead shows example of a non-proliferating Sertoli cell; scale bars represent 50 μm, or 25 μm
for insets. (B) Data shows (Bi) density of Sertoli cells measured by the % area of the seminiferous tubules expressing Sox9, following cisplatin (red)
or carboplatin (blue) treatment as well as (Bii) number of manually counted proliferating Sertoli cells. n =6 for all experimental conditions. Data are
mean+ SEM; columns with different letters are statistically significantly different to each other (P < 0.05).
prevent or reduce chemotherapy-induced gonadotoxicity. Based on
our short-term study, carboplatin may be even more damaging to
the ovary than cisplatin, since only two to five times the carboplatin
concentration induced equivalent damage as the cisplatin, whereas
patients can receive up to 15 times the dose. It will be important for
further studies to focus on clinical paediatric patients, to determine
whether the same conclusions can be drawn on future fertility as from
this short-term animal study.
For both cisplatin and carboplatin, higher doses were required to
observe significant levels of germ cell/follicle damage/loss to the ovar-
ian tissue in comparison to the testes, suggesting the testis may bemore
sensitive to the platinum alkylating-like agents. This has previously been
noted for other chemotherapy drugs including irinotecan (Lopes et al.,
2016), although that could, in part at least, be due to differences in the
culture conditions of ovarian and testicular tissue. It is also important
to bear in mind that, whereas there would be the potential for even a
few surviving spermatogonial stem cells to (partially) repopulate the
testis after treatment, any loss of oocytes would be irreplaceable.
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Nonetheless, in agreement with our current and previous (Lopes et al.,
2016) findings that the testis may be more sensitive to chemotherapy
treatment than the ovary, a study following survivors of childhood
cancer that had been treated with alkylating agents found that the
effects on male fertility were more pronounced than those on female
fertility (Chow et al., 2016); the decrease in the percentage of male
survivors siring a live birth compared to their siblings was greater than
the decrease in the percentage of female survivors having live births
compared to their siblings. Additional studies are required to determine
the functional deficits following cisplatin or carboplatin treatment and
the long-term impact on recovery and subsequent effects on fertility.
Ovarian toxicity as a result of chemotherapy treatment can lead
to infertility and premature ovarian insufficiency (POI) due to direct
damage to the ovary depleting the ovarian reserve of primordial
follicles (reviewed in Ben-Aharon and Shalgi, 2012; Morgan et al., 2012;
Bedoschi et al., 2016; Spears et al., 2019). Primordial follicles form
before birth when the germ cells leave the mitotic phase, enter meiosis,
arrest at prophase I and become surrounded by pregranulosa cells.
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These primordial follicles represent a female’s reproductive potential
and are activated into growing follicles throughout the reproductive
lifespan of the female (McGee and Hsueh, 2000). Loss of primordial
follicles, through for example chemotherapy treatment, can lead to
POI and early menopause (Wallace et al., 2005). Our study shows that
cisplatin and carboplatin exposure leads to a reduction in the number of
primordial follicles aligning with previous studies on cisplatin (Meirow,
2000; Gonfloni et al., 2009; Morgan et al., 2013). All follicles, including
those at the primordial state, were damaged in our study, showing that
direct effects of the drugs on the primordial follicles is at least part of
the reason for the primordial follicle loss. Overall, primordial follicle
loss may be a result of either direct damage to the primordial follicles
and/or accelerated activation of primordial follicles into the growth
phase as a result of the drugs depleting the growing follicular pool
that usually inhibits activation (Meirow et al., 2010; Findlay et al., 2015).
In the literature, the underlying mechanism for primordial follicle loss
following exposure to platinum alkylating-like agents is still debated,
with some studies showing direct damage to the primordial follicles
(Nguyen et al., 2019) and others suggesting that accelerated activation
contributes to loss of primordial follicles following cisplatin treatment
(Morgan et al., 2013; Chang et al., 2015).
The specific cell typewithin primary ovarian follicles that was affected
by cisplatin or carboplatin treatment was further investigated, to deter-
mine whether the oocyte and/or granulosa cells were targeted. The
oocyte and surrounding granulosa cells are co-dependent upon each
other for oocyte maturation and folliculogenesis, therefore damage
to one cell type will ultimately result in death of the latter, but it is
also important to know which cell type is affected first if protective
treatments are to be developed. Our results show that for primary
follicles, both cisplatin and carboplatin primarily damage granulosa cells.
Previous studies have focused on the oocyte or have combined primary
follicles with transitional follicles to represent the growing follicular
pool (Gonfloni et al., 2009; Morgan et al., 2013). These studies have
shown effects of cisplatin on the oocyte, as a result of DNA damage,
accumulation of Tap63 and activation of apoptotic pathways (Gonfloni
et al., 2009; Kerr et al., 2012; Kim et al., 2013, 2019; Morgan et al.,
2013; Rossi et al., 2017;Nguyen et al., 2018, 2019). These studies came
to the conclusion that cisplatin targeted the oocyte, whereas our study
found that for primary follicles, mainly granulosa cells were damaged
following cisplatin treatment. The difference between these findings
and the results of the present study is not clear, but could in part, be
due to differences in mouse line (here CD1 line) or age of animal (here,
pnd 4). The mechanism underlying granulosa cell damage following
treatment with platinum containing alkylating-like agents has yet to be
investigated fully.
For the testis, there is much less known about the effects of
chemotherapy treatment on the prepubertal gonad than that of
the adult. The paucity of prepubertal studies could possibly be due
to limited animal model systems to investigate prepubertal testis
development and/or to the fact that the prepubertal testis was once
considered relatively inactive and therefore thought to be protected
from any chemotherapy-induced damage (Rivkees and Crawford,
1988; Rey, 1999). The testis undergoes important developmental
processes during prepuberty, including germ cell proliferation and
Sertoli cell functional maturation, any of which could be affected
by chemotherapy drugs (Chemes, 2001; Allen et al., 2018). The
present study shows that both cisplatin and carboplatin reduce the
.
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population of proliferating germ cells in the prepubertal testis. The
proliferative capacity was analysed during a 24-h period starting 24 h
after drug exposure had finished; therefore, the loss of proliferating
cells could either be a result of the drugs targeting and killing the
proliferating cells or a consequence of the drugs preventing subsequent
germ cell proliferation. The underlying mechanism of action of the
platinum alkylating-like agents has been studied following cisplatin
treatment and indicates that cisplatin induces DNA damage and
activates apoptotic pathways as shown through increased expression
of cleaved caspases 3, TUNEL-positive cells and γH2AX expression
(Lirdi et al., 2008; Favareto et al., 2011; Smart et al., 2018). The
germ cell population at this stage of development is predominantly
composed of undifferentiated type A spermatogonia (spermatogonial
stem cell; SSC) as well as differentiating spermatogonia type B (de Rooij
and Russell, 2000; Ehmcke et al., 2006). Further investigations should
therefore focus on the specific germ cell types targeted, since our study
used a generic marker for germ cells, MVH. Research is focusing on
SSCs, since maintenance of this population is crucial for later fertility
(Zohni et al., 2012; Zohni et al., 2012). SSCs are vulnerable to cisplatin
treatment, with survival of isolated SSCs decreased in culture (Marcon
et al., 2010; Liu et al., 2014; Shabani et al., 2016) and PLZF-positive
germ cells (SSCs) reduced in cultured testis tissue following cisplatin
exposure (Smart et al., 2018).
The density of the Sertoli cell population was unaffected by either
cisplatin or carboplatin exposure as previously shown in Smart et al.
(2018). However, there is the potential that functional maturation of
these cells could be affected, resulting in Sertoli cells that are not
capable of fully supporting germ cells through spermatogenesis in the
adult (Chemes, 2001; Sharpe et al., 2003). Indeed, previous studies
have found a decrease in Sertoli cell viability (Aslani et al., 2017) follow-
ing treatment as well as functional deficits through reduced androgen
binding protein or transferrin production (Nambu et al., 1995; Favareto
et al., 2011). Here, additional studies would be required to investigate
the maturation of these cells, through for example analysis of anti-
Müllerian hormone and inhibin B (Dere et al., 2013). In addition to
the Sertoli cells, other somatic cells within the testis, including the
endocrine Leydig cells and peritubular myoid cells, could be affected
by chemotherapy treatment but have yet to be fully investigated. Initial
studies using a mouse model found no impact of cisplatin on the
density of the Leydig cell population (Smart et al., 2018); however,
there have yet to be any studies focusing on steroidogenesis or testos-
terone production following prepubertal exposure to either cisplatin
or carboplatin.
In summary, working within the range of drug concentrations found
in patient serum, results here show that clinically relevant concen-
trations of cisplatin and carboplatin have similar gonadotoxic effects
on the prepubertal mouse ovary and testis. Both platinum-alkylating
agents reduced the number and health of ovarian follicles. In the
testis, either drug reduced the density of the proliferating germ cell
population, while no effect on the density of Sertoli cells was seen.
Since both drugs had an impact on gonadal tissues within clinically
relevant concentrations, we conclude from this in vitro animal model
study that replacing cisplatin with carboplatin in treatment protocols
may not result in any additional protection of the gonadal tissues
from the damaging effects of the drugs. Further clinical studies are
required before any recommendations for paediatric patients can
be made.
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